Pfizer’s BRAFTOVI Regimen Nearly Doubles Progression-Free Survival in mCRC
The Phase 3 BREAKWATER study showed BRAFTOVI combined with cetuximab and FOLFIRI nearly doubled median progression-free survival to 15.2 months compared to 8.3 months with the comparator.
Phase III
metastatic colorectal cancer
Status
Active
Sponsor
Pfizer
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The significant efficacy data from the BREAKWATER study positions BRAFTOVI as a leading treatment option for a previously underserved patient population. This advancement not only enhances Pfizer's competitive edge but also has the potential to influence treatment guidelines and market dynamics in oncology.
Recommended action
Humanexa recommends Monitor: Monitoring is recommended to track the uptake of BRAFTOVI in clinical settings and to observe any emerging competitive responses or changes in treatment guidelines.
Analysis
Monitor for further data releases from the BREAKWATER trial and updates on market uptake and physician adoption of the BRAFTOVI regimen.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.